Skystar has purchased an exclusive aquaculture vaccine technology from and signed a collaborative research and development agreement with China’s Fourth Military Medical University (FMMU) for RMB 8m, granting
Oxagen has completed the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its oral CRTH2 (DP2) antagonist. The study, which
Protalix has completed New Drug Application (NDA) submission with the FDA for Taliglucerase Alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of gaucher’s disease.
Atrium Medical has enrolled first patient in the Infuse AMI trial. Infuse AMI is a multi-center, multi-national, prospective, randomised, single blind trial, examining how patients with heart attacks
Nabi Biopharmaceuticals (Nabi) has initiated a Phase I/II clinical trial for two of the antigens in the PentaStaph vaccine candidate, which is now owned by GlaxoSmithKline Biologicals (GSK).
Skinvisible and Alto Pharmaceuticals (Alto) have entered into a license agreement for DermSafe, Skinvisible’s antimicrobial hand sanitiser lotion that recently completed clinical studies proving it kills the H1N1
Cumberland Pharmaceuticals (Cumberland) has entered into an exclusive agreement with DB Pharm Korea for the commercialisation of Caldolor (ibuprofen) injection in South Korea. Designed to treat pain and
Pacific Beach BioSciences has granted non-exclusive rights to a pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage
Regenerx Biopharmaceuticals (Regenerx) has completed and analysed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. RGN-352 is an
Osteologix anticipates of filing a marketing application in 2011 in the EU for strontium therapy, NB S101 (Strontium Malonate). If successful, this is expected to be Osteologix’ first
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.